Published by
@ShahidNShah
@ShahidNShah
September 26 to September 28, 2023
Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States
With the approval of the second-ever KRAS G12C inhibitor, the field can once again celebrate irrevocable proof that RAS is druggable! However, with so many KRAS G12C drugs in clinic, the field is now turning its eyes to the next generation of RAS therapies, specifically those that can target more mutations, more RAS isoforms, and more indications And so, the 5th RAS Targeted Drug Development Summit arrives as the only industry-dedicated, end-to-end forum to accelerate your best-in-class RAS therapies from conception through to commercialization. As the only industry-dedicated, end-to-end meeting focused on the next-generation of drugs targeting RAS cancers, the 5th RAS Targeted Drug Development Summit will bring together 150+ key opinion leaders to accelerate RAS-targeted drug discovery, advance pre-clinical drugs to clinic, and optimize translational and clinical development.
Continue reading at ras-drugdevelopment.com
September 26 to September 28, 2023
Boston Convention and Exhibition Center, 415 Summer Street, Boston, Massachusetts, 02210, United States
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Media LLC. All Rights Reserved.
Built on Apr 19, 2024 at 8:35am